Firefly Neuroscience's AI-Powered EEG Analytics Show Promise in Drug Development and Neuropsychiatric Care

Firefly Neuroscience Unveils Groundbreaking EEG Analytics in Brain Health

Firefly Neuroscience, Inc. (NASDAQ: AIFF), an AI-driven company focused on improving brain health outcomes, has announced two significant publications demonstrating the utility of their advanced EEG analytics in drug development and neuropsychiatric care 1

1

2

2

. The company's FDA-cleared Brain Network Analytics (BNA™) platform is showing promise in providing objective measures of drug efficacy and cognitive change.

Innovative Approach to Neuropharmacology

The first study, conducted in collaboration with Novartis, explored the use of EEG in assessing the effects of MIJ821, a potential antidepressant drug. Key findings include:

1. Dose-dependent EEG changes were observed, linking post-dose resting EEG activity to dosage.
2. EEG revealed changes consistent with ketamine's known effects, such as increased gamma power and decreased alpha power.
3. The study paves the way for EEG-driven biomarker development, potentially improving drug dose selection and patient-specific treatment strategies 1

   1

   .

Advancing Psychiatric Care with Objective Cognitive Assessments

The second study focused on using EEG-based tools to assess cognitive changes in patients with Major Depressive Disorder (MDD) during treatment. Notable outcomes include:

1. Baseline brain activation latencies, measured through Firefly's BNA™ technology, were longer in MDD patients compared to controls but normalized post-treatment.
2. The results reflected improved cognitive functioning independent of antidepressant effects.
3. Firefly's BNA™ pipeline for automatic EEG analysis offers a scalable solution for evaluating treatment efficacy in MDD patients 2

   2

   .

AI-Powered Brain Health Innovation

Firefly's BNA™ technology leverages artificial intelligence and machine learning to analyze a proprietary database of over 17,000 patient EEGs across twelve disorders. This comprehensive approach allows for:

1. Enhanced diagnostic accuracy for mental and cognitive disorders.
2. Improved evaluation of suitable therapies and drugs for optimal patient outcomes.
3. Potential transformation of complex brain data into actionable insights for clinicians and researchers 1

   1

   2

   2

   .

Commercial Implications and Future Prospects

Firefly Neuroscience is now launching BNA™ commercially, targeting two primary markets:

1. Pharmaceutical companies engaged in drug research and clinical trials.
2. Medical practitioners for clinical use in diagnosing and monitoring neurological and mental disorders 1

   1

   .

Greg Lipschitz, Executive Chairman of Firefly, expressed pride in the company's position at the forefront of EEG innovation, emphasizing the technology's potential to transform complex brain data into actionable insights 2

2

.

As Firefly Neuroscience continues to develop its AI-powered solutions, the company aims to revolutionize brain health diagnostics and treatment monitoring for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD 1

1

2

2

.